{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"The objective response rate will be estimated by arm along with an exact 95% binomial confidence interval","groups":[{"description":"Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive metformin hydrochloride PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.\n\nExternal Beam Radiation Therapy: Undergo External Beam Radiation Therapy\n\nMetformin Hydrochloride: Given orally","id":"OG000","title":"Arm I (EBRT, Metformin Hydrochloride)"},{"description":"Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive placebo PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.\n\nExternal Beam Radiation Therapy: Undergo External Beam Radiation Therapy\n\nPlacebo: Given orally","id":"OG001","title":"Arm II (EBRT, Placebo)"}],"populationDescription":"Due to insufficient accrual, statistical results cannot be reported.","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Objective Response Rate","type":"SECONDARY"}